FY2025 EPS Estimate for ADC Therapeutics Boosted by Analyst

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of ADC Therapeutics in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings per share of ($1.99) for the year, up from their previous forecast of ($2.25). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share.

A number of other research firms have also commented on ADCT. Stephens raised their price target on ADC Therapeutics from $6.00 to $8.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Guggenheim dropped their target price on shares of ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Monday, March 31st. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of ADC Therapeutics in a report on Monday, March 31st. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $8.00 price objective on shares of ADC Therapeutics in a research report on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ADC Therapeutics presently has an average rating of "Buy" and a consensus price target of $7.75.

ADC Therapeutics Stock Performance

ADCT stock traded up $0.23 during midday trading on Monday, hitting $2.20. 984,907 shares of the company's stock were exchanged, compared to its average volume of 607,331. ADC Therapeutics has a one year low of $1.05 and a one year high of $4.13. The company has a market cap of $218.49 million, a PE ratio of -0.92 and a beta of 1.54. The stock's fifty day moving average price is $1.44 and its 200-day moving average price is $1.81.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.02. The firm had revenue of $23.03 million for the quarter, compared to the consensus estimate of $17.71 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Woodline Partners LP bought a new stake in ADC Therapeutics in the 4th quarter valued at approximately $3,848,000. Orbimed Advisors LLC raised its holdings in shares of ADC Therapeutics by 31.6% in the fourth quarter. Orbimed Advisors LLC now owns 5,968,451 shares of the company's stock valued at $11,877,000 after purchasing an additional 1,434,650 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of ADC Therapeutics in the fourth quarter worth $1,426,000. Platinum Investment Management Ltd. boosted its holdings in ADC Therapeutics by 11.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,612,556 shares of the company's stock worth $3,209,000 after purchasing an additional 168,040 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in ADC Therapeutics by 411.1% during the first quarter. AQR Capital Management LLC now owns 201,170 shares of the company's stock worth $284,000 after purchasing an additional 161,808 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.